These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 23413016)

  • 1. Genetic blockade of insulin-like growth factor-1 receptor via recombinant adenovirus in lung cancer can be enhanced by the histone deacetylase inhibitor, vorinostat.
    Park MY; Kim DR; Eo EY; Lim HJ; Park JS; Cho YJ; Yoon HI; Lee JH; Lee CT
    J Gene Med; 2013; 15(3-4):115-22. PubMed ID: 23413016
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adenovirus expressing shRNA to IGF-1R enhances the chemosensitivity of lung cancer cell lines by blocking IGF-1 pathway.
    Lee YJ; Imsumran A; Park MY; Kwon SY; Yoon HI; Lee JH; Yoo CG; Kim YW; Han SK; Shim YS; Piao W; Yamamoto H; Adachi Y; Carbone DP; Lee CT
    Lung Cancer; 2007 Mar; 55(3):279-86. PubMed ID: 17134788
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of vorinostat and adenovirus-TRAIL exhibits a synergistic antitumor effect by increasing transduction and transcription of TRAIL in lung cancer cells.
    Kim DR; Park MY; Lee CS; Shim SH; Yoon HI; Lee JH; Sung MW; Kim YS; Lee CT
    Cancer Gene Ther; 2011 Jul; 18(7):467-77. PubMed ID: 21455254
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activation of insulin-like growth factor receptor signaling mediates resistance to histone deacetylase inhibitors.
    Kim JS; Lee SC; Min HY; Park KH; Hyun SY; Kwon SJ; Choi SP; Kim WY; Lee HJ; Lee HY
    Cancer Lett; 2015 Jun; 361(2):197-206. PubMed ID: 25721083
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination therapy with conditionally replicating adenovirus and replication defective adenovirus.
    Lee CT; Park KH; Yanagisawa K; Adachi Y; Ohm JE; Nadaf S; Dikov MM; Curiel DT; Carbone DP
    Cancer Res; 2004 Sep; 64(18):6660-5. PubMed ID: 15374981
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting for insulin-like growth factor-I receptor with short hairpin RNA for human digestive/gastrointestinal cancers.
    Wang Y; Adachi Y; Imsumran A; Yamamoto H; Piao W; Li H; Ii M; Arimura Y; Park MY; Kim D; Lee CT; Carbone DP; Imai K; Shinomura Y
    J Gastroenterol; 2010 Feb; 45(2):159-70. PubMed ID: 19902140
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant adenoviruses expressing dominant negative insulin-like growth factor-I receptor demonstrate antitumor effects on lung cancer.
    Lee CT; Park KH; Adachi Y; Seol JY; Yoo CG; Kim YW; Han SK; Shim YS; Coffee K; Dikov MM; Carbone DP
    Cancer Gene Ther; 2003 Jan; 10(1):57-63. PubMed ID: 12489029
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blockade of IGF-1 receptor tyrosine kinase has antineoplastic effects in hepatocellular carcinoma cells.
    Höpfner M; Huether A; Sutter AP; Baradari V; Schuppan D; Scherübl H
    Biochem Pharmacol; 2006 May; 71(10):1435-48. PubMed ID: 16530734
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination therapy of conditionally replicating adenovirus and histone deacetylase inhibitors.
    Kim DR; Park MY; Lim HJ; Park JS; Cho YJ; Lee SW; Yoon HI; Lee JH; Kim YS; Lee CT
    Int J Mol Med; 2012 Feb; 29(2):218-24. PubMed ID: 22075951
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective inhibition of SCLC growth by the A12 anti-IGF-1R monoclonal antibody correlates with inhibition of Akt.
    Yeh J; Litz J; Hauck P; Ludwig DL; Krystal GW
    Lung Cancer; 2008 May; 60(2):166-74. PubMed ID: 18006183
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of three approaches for inhibiting insulin-like growth factor I receptor and their effects on NSCLC cell lines in vitro.
    Cosaceanu D; Carapancea M; Alexandru O; Budiu R; Martinsson HS; Starborg M; Vrabete M; Kanter L; Lewensohn R; Dricu A
    Growth Factors; 2007 Feb; 25(1):1-8. PubMed ID: 17454144
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insulin-like growth factor-1 receptor inhibition induces a resistance mechanism via the epidermal growth factor receptor/HER3/AKT signaling pathway: rational basis for cotargeting insulin-like growth factor-1 receptor and epidermal growth factor receptor in hepatocellular carcinoma.
    Desbois-Mouthon C; Baron A; Blivet-Van Eggelpoël MJ; Fartoux L; Venot C; Bladt F; Housset C; Rosmorduc O
    Clin Cancer Res; 2009 Sep; 15(17):5445-56. PubMed ID: 19706799
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined histone deacetylase and NF-kappaB inhibition sensitizes non-small cell lung cancer to cell death.
    Rundall BK; Denlinger CE; Jones DR
    Surgery; 2004 Aug; 136(2):416-25. PubMed ID: 15300209
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proteasome inhibition sensitizes non-small cell lung cancer to histone deacetylase inhibitor-induced apoptosis through the generation of reactive oxygen species.
    Denlinger CE; Rundall BK; Jones DR
    J Thorac Cardiovasc Surg; 2004 Nov; 128(5):740-8. PubMed ID: 15514602
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic blockade of the insulin-like growth factor 1 receptor for human malignancy.
    Adachi Y; Lee CT; Carbone DP
    Novartis Found Symp; 2004; 262():177-89; discussion 190-2, 265-8. PubMed ID: 15562829
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic blockade of the insulin-like growth factor-I receptor: a promising strategy for human pancreatic cancer.
    Min Y; Adachi Y; Yamamoto H; Ito H; Itoh F; Lee CT; Nadaf S; Carbone DP; Imai K
    Cancer Res; 2003 Oct; 63(19):6432-41. PubMed ID: 14559833
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histone deacetylase inhibitor vorinostat suppresses the growth of uterine sarcomas in vitro and in vivo.
    Hrzenjak A; Moinfar F; Kremser ML; Strohmeier B; Petru E; Zatloukal K; Denk H
    Mol Cancer; 2010 Mar; 9():49. PubMed ID: 20202195
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antitumor effects of an adenovirus expressing antisense insulin-like growth factor I receptor on human lung cancer cell lines.
    Lee CT; Wu S; Gabrilovich D; Chen H; Nadaf-Rahrov S; Ciernik IF; Carbone DP
    Cancer Res; 1996 Jul; 56(13):3038-41. PubMed ID: 8674059
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The insulin-like growth factor receptor 1 is a promising target for novel treatment approaches in neuroendocrine gastrointestinal tumours.
    Höpfner M; Baradari V; Huether A; Schöfl C; Scherübl H
    Endocr Relat Cancer; 2006 Mar; 13(1):135-49. PubMed ID: 16601284
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The mechanism of action of the histone deacetylase inhibitor vorinostat involves interaction with the insulin-like growth factor signaling pathway.
    Sarfstein R; Bruchim I; Fishman A; Werner H
    PLoS One; 2011; 6(9):e24468. PubMed ID: 21931726
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.